Melissa M. Hazen

ORCID: 0000-0002-0009-521X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Autoimmune and Inflammatory Disorders Research
  • Immune Cell Function and Interaction
  • Adolescent and Pediatric Healthcare
  • Immunodeficiency and Autoimmune Disorders
  • Monoclonal and Polyclonal Antibodies Research
  • Glycosylation and Glycoproteins Research
  • T-cell and B-cell Immunology
  • Systemic Lupus Erythematosus Research
  • Inflammasome and immune disorders
  • Hearing, Cochlea, Tinnitus, Genetics
  • Acute Lymphoblastic Leukemia research
  • Vestibular and auditory disorders
  • Galectins and Cancer Biology
  • Blood disorders and treatments
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Childhood Cancer Survivors' Quality of Life
  • Parvovirus B19 Infection Studies
  • Pediatric Pain Management Techniques
  • Family and Disability Support Research
  • Eosinophilic Esophagitis
  • Kawasaki Disease and Coronary Complications
  • Platelet Disorders and Treatments
  • Evaluation of Teaching Practices
  • Gout, Hyperuricemia, Uric Acid

Boston Children's Hospital
2015-2025

Harvard University
2014-2025

Children's Healthcare of Atlanta
2023

Boston Children's Museum
2010-2023

Dana-Farber Cancer Institute
2022

Hospital for Sick Children
2018-2021

University of Toronto
2021

Cochlear (Australia)
2021

SickKids Foundation
2021

Dana-Farber/Boston Children's Cancer and Blood Disorders Center
2015

Poor outcomes in COVID-19 correlate with clinical and laboratory features of cytokine storm syndrome. Broad screening for early, targeted antiinflammatory therapy may prevent immunopathology could help conserve limited health care resources. While studies are ongoing, extrapolating from experience syndromes benefit the multidisciplinary teams caring patients severe COVID-19.

10.1002/art.41285 article EN Arthritis & Rheumatology 2020-04-15

BACKGROUND. Pediatric SARS–CoV-2 infection can be complicated by a dangerous hyperinflammatory condition termed multisystem inflammatory syndrome in children (MIS-C). The clinical and immunologic spectrum of MIS-C its relationship to other conditions childhood have not been studied detail.

10.1172/jci141113 article EN Journal of Clinical Investigation 2020-07-23

Inherited, complete deficiency of human HOIL-1, a component the linear ubiquitination chain assembly complex (LUBAC), underlies autoinflammation, infections, and amylopectinosis. We report clinical description molecular analysis novel inherited disorder LUBAC complex. A patient with multiorgan combined immunodeficiency, subclinical amylopectinosis, systemic lymphangiectasia, is homozygous for mutation in HOIP, gene encoding catalytic LUBAC. The missense allele (L72P, PUB domain) at least...

10.1084/jem.20141130 article EN The Journal of Experimental Medicine 2015-05-25

To investigate the characteristics and risk factors of a novel parenchymal lung disease (LD), increasingly detected in systemic juvenile idiopathic arthritis (sJIA).In multicentre retrospective study, 61 cases were investigated using physician-reported clinical information centralised analyses radiological, pathological genetic data.LD was associated with distinctive features, including acute erythematous clubbing high frequency anaphylactic reactions to interleukin (IL)-6 inhibitor,...

10.1136/annrheumdis-2019-216040 article EN Annals of the Rheumatic Diseases 2019-09-27

Abstract Objective Systemic juvenile idiopathic arthritis (JIA) is characterized by fevers, rash, and arthritis, for which interleukin‐1 (IL‐1) IL‐6 inhibitors appear to be effective treatments. Pulmonary arterial hypertension (PAH), interstitial lung disease (ILD), alveolar proteinosis (AP) have recently been reported with increased frequency in systemic JIA patients. Our aim was characterize compare patients these complications a larger cohort of Methods who developed PAH, ILD, and/or AP...

10.1002/acr.21889 article EN Arthritis Care & Research 2012-11-08

Juvenile idiopathic arthritis (JIA) is a heterogeneous group of diseases, comprising seven categories. Genetic data could potentially be used to help redefine JIA categories and improve the current classification system. The human leucocyte antigen (HLA) region strongly associated with JIA. Fine-mapping was performed look for similarities differences in HLA associations between define correspondences adult inflammatory arthritides.Dense genotype from region, Immunochip array 5043 cases 14...

10.1136/annrheumdis-2016-210025 article EN cc-by Annals of the Rheumatic Diseases 2016-12-20

Hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) were historically thought to be distinct entities, often managed in isolation. In fact, these conditions are closely related. A collaborative approach, which incorporates expertise from subspecialties that previously treated HLH/MAS independently, is needed. We leveraged quality improvement (QI) techniques the form of an Evidence-Based Guideline (EBG) build consensus across disciplines on diagnosis treatment...

10.1186/s12969-019-0309-6 article EN cc-by Pediatric Rheumatology 2019-02-14

Abstract The clinical syndromes of hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are both characterized by dysregulated inflammation with prolonged fever, hepatosplenomegaly, coagulopathy, hematologic cytopenias, evidence hemophagocytosis in the bone marrow or liver. While HLH is either inherited acquired, children severe rheumatic diseases, most notably systemic juvenile idiopathic arthritis, at risk for MAS. phenotypic similarity between MAS raises...

10.1002/art.23199 article EN Arthritis & Rheumatism 2008-01-31

Although autoimmunity and hyperinflammation secondary to recombination activating gene (RAG) deficiency have been associated with delayed diagnosis even death, our current understanding is limited primarily small case series.

10.1016/j.jaip.2019.02.038 article EN cc-by-nc-nd The Journal of Allergy and Clinical Immunology In Practice 2019-03-12

Systemic juvenile idiopathic arthritis (sJIA) begins with fever, rash, and high-grade systemic inflammation but commonly progresses to a persistent afebrile arthritis. The basis for this transition is unknown. To evaluate role lymphocyte polarization, we characterized T cells from patients acute chronic sJIA using flow cytometry, mass RNA sequencing. Acute each featured an expanded population of activated Tregs uncommon in healthy controls or children nonsystemic JIA. In sJIA, expressed...

10.1172/jci.insight.132508 article EN cc-by JCI Insight 2020-03-25

Rheumatoid arthritis culminates in joint destruction that, mouse models of disease, is supported by innate immune molecules, including Fcγ receptors (FcγR) and complement. However, these findings may not be predictive the outcome humans, given structural differences between murine human activating FcγR on neutrophils, a prominent component exudates. The aim this study was to examine role neutrophil FcγRIIa development probe underlying mechanism which initiates disease.K/BxN serum...

10.1002/art.30141 article EN Arthritis & Rheumatism 2010-11-12

Objective Treg cell–mediated suppression of Teff cells is impaired in juvenile idiopathic arthritis (JIA); however, the basis for this dysfunction incompletely understood. Animal models autoimmunity and immunodeficiency demonstrate that a diverse cell repertoire essential to maintain function. The present study was undertaken investigate repertoires JIA. Methods (CD4+CD25+CD127 low ) (CD4+CD25−) were isolated from peripheral blood synovial fluid obtained JIA patients, healthy controls,...

10.1002/art.39606 article EN Arthritis & Rheumatology 2016-01-27

Objective Although interleukin‐1 (IL‐1)/IL‐6 inhibitors are effective therapies for systemic juvenile idiopathic arthritis (JIA), some patients develop eosinophilia and lung disease during treatment. This study was undertaken to retrospectively evaluate incidence risk factors describe outcomes in IL‐1/IL‐6 inhibitor–exposed with JIA. Methods Among JIA at our institution exposed (1995–2022), we compared rate of other JIA, stratified by medication class (IL‐1/IL‐6 inhibitors, cytokine...

10.1002/acr.25129 article EN Arthritis Care & Research 2023-04-11

Oligoarticular juvenile idiopathic arthritis (oligo JIA) is the most common form of chronic inflammatory in children, yet cause this disease remains unknown. To understand immune responses oligo JIA, we immunophenotyped synovial fluid T cells with flow cytometry, bulk RNA-Seq, single-cell RNA-Seq (scRNA-Seq), DNA methylation studies, and Treg suppression assays. In fluid, CD4+, CD8+, γδ expressed Th1-related markers, whereas Th17 were not enriched. Th1 skewing was prominent CD4+ cells,...

10.1172/jci.insight.149185 article EN cc-by JCI Insight 2021-08-17

T peripheral helper (Tph) cells, identified in the synovium of adults with seropositive rheumatoid arthritis, drive B cell maturation and antibody production non-lymphoid tissues. We sought to determine if similarly dysregulated cell-B interactions underlie another form inflammatory juvenile oligoarthritis (oligo JIA). Clonally expanded Tph cells able promote preferentially accumulated synovial fluid (SF) oligo JIA patients antinuclear antibodies (ANA) compared autoantibody-negative...

10.3389/fimmu.2022.1068399 article EN cc-by Frontiers in Immunology 2023-01-05

To describe the selection, development, and implementation of quality measures (QMs) for juvenile idiopathic arthritis (JIA) by Pediatric Rheumatology Care Outcomes Improvement Network (PR-COIN), a multihospital learning health network using improvement methods leveraging QMs to drive improved outcomes across JIA population since 2011.An American College Rheumatology-endorsed multistakeholder process previously selected initial QMs. Clinicians in PR-COIN parents children with collaboratively...

10.1002/acr.25168 article EN cc-by-nc-nd Arthritis Care & Research 2023-06-12

Health-related social needs (HRSN) have a significant impact on health outcomes. While screening is prevalent in paediatric primary care settings, little evidence exists regarding the feasibility of HRSN rheumatology clinics. Individuals with rheumatic disease frequent longitudinal visits, therefore it important to understand that may hinder optimal outcomes this population. The objectives study were burden and contextualize universal busy clinic. team secured funding for full-time worker...

10.1093/rap/rkaf014 article EN cc-by-nc Rheumatology Advances in Practice 2025-01-30

Objective Disordered T peripheral helper (Tph)‐B cell interactions have been implicated in several forms of inflammatory arthritis, including oligoarticular juvenile idiopathic arthritis (oligo JIA). We sought to evaluate the Tph‐B axis oligo JIA through an analysis intra‐articular B cells. Methods cells from blood and synovial fluid (SF) 44 children with were compared those tonsils controls. Flow cytometry, receptor (BCR) repertoire analysis, autoantibody profiling used characterize Results...

10.1002/art.43157 article EN Arthritis & Rheumatology 2025-03-17

Objective Treat to target (T2T) is a strategy of adjusting treatment until reached. An international task force recommended T2T for juvenile idiopathic arthritis (JIA) treatment. Implementing in standard and reliable way clinical practice requires agreement on critical elements (1) setting, (2) strategy, (3) identifying barriers implementation, (4) patient eligibility. A consensus conference was held among Pediatric Rheumatology Care Outcomes Improvement Network (PR-COIN) stakeholders inform...

10.3899/jrheum.210709 article EN The Journal of Rheumatology 2022-02-01

Rheumatoid arthritis is associated with an excess of agalactosylated (G0) IgG that considered relatively proinflammatory. Assessment this association in juvenile idiopathic (JIA) complicated by age-dependent glycan variation. The aim study was to conduct the first large-scale survey glycans healthy children and patients JIA, a focus on early childhood, time peak JIA incidence.IgG from disease-modifying antirheumatic drug-naive were characterized using high-performance liquid chromatography....

10.1002/art.34507 article EN Arthritis & Rheumatism 2012-05-02
Coming Soon ...